About Magellan Biosciences, Inc.

Company description

An emerging leader in the clinical-diagnostics and biomedical-research markets, Magellan Biosciences, Inc. was established in October 2004. Today, Magellan develops and commercializes worldwide a broad range of products that improve clinical outcomes, including point-of-care assays and analyzers, automated clinical-assay workstations, diagnostic systems and assays, and related consumables and services. Within the biomedical-research market, we focus on our customer's analytical challenges by offering a suite of high-performance detection products that enable customers to perform the rigorous scientific inquiries that lead to breakthrough discoveries across a range of critical applications.

Magellan serves customers through its wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TREK Diagnostic Systems. Headquartered about 30 miles northwest of Boston in Chelmsford, Massachusetts, Magellan employs a talented, multidisciplinary staff of more than 300 worldwide who work cross-functionally to provide quick response to customers and to solve complex product-development and technical-support problems.

Growth strategy

Our goal is to deliver strong and consistent revenue growth by providing innovative products and services to an expanded customer base – internal growth – and through acquisitions. We believe we can deliver through a multi-pronged growth strategy comprising four elements:

• New product development
• Recurring revenues
• New applications
• Acquisitions

But a company's success should not be measured by revenue growth alone. Our goal is to deliver profitable growth, and continually enhance the bottom line. We will invest substantial resources in R&D, in people, and in necessary infrastructure – all that's required to build a world-class company – but we plan to do it smart! How? By our unwavering commitment to quality and to improving how we do things each and every day. By sharing company-wide the strengths, skills, and resources that abound in each of our companies. And by exploiting the opportunities that come from scale; a growing $80 million company has prospects that would be beyond the reach of a smaller enterprise.

Magellan Companies:

Ownership and financial information

A privately held company, Magellan Biosciences is majority-owned by Ampersand Ventures. Other investors include Abingworth Management, Boston Community Venture Fund, Hambrecht & Quist Capital Management, KBL Healthcare Ventures, New England Partners Capital LP, and Nexus Medical Partners II SICAR. As such, we do not release our company financials. Our goal is to deliver double-digit revenue growth, balanced between internal growth and acquisitions.

Executive management team

Robert J. Rosenthal, PhD – President and Chief Executive Officer

Michael Mullen – Chief Financial Officer

Darren Braccia – Vice President of Business Development

Steven E. Diamond, PhD – Chief Scientific Officer

Philip Ayers – Corporate Counsel

Adrian Bunce – President, Dynex Technologies

Mike Burke – President, TREK Diagnostic Systems

Board of directors

Herbert Hooper, PhD – Magellan Biosciences Chairman; Ampersand Ventures Managing General Partner (private equity investments)

Stuart A. Auerbach – Ampersand Ventures General Partner (private equity investments)

Michael F. Bigham – Abingworth Management Director, responsible for the Boston office

Heiner Dreismann, PhD – Former President and CEO, Roche Molecular Diagnostics (PCR-based (polymerase chain reaction) molecular diagnostic tests)

Laurence R. McCarthy, PhD – Former President and CEO of Focus Diagnostics, Inc., (developer of novel assays and diagnostic-testing services)

Daniel R. Omstead, Eng.ScD – President and CEO, Hambrecht & Quist Capital Management

Robert J. Rosenthal, PhD – Magellan Biosciences President and CEO

Michael E. Woehler, PhD – President and CEO, Medifacts International (contract clinical-trial services to the pharmaceutical, biotech, and medical-device industries)

Back to top